Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art

Heart Failure (HF) is a cardiovascular condition with high morbidity and mortality that conditions one of the most critical problems in public health. Despite advances recent decades, patients continue to have major events marked reduction their quality life. Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2 Inhibitors) initially entered market treat hyperglycemia type diabetes mellitus (T2DM), however discovery benefits HF, regardless presence or absence T2DM positioned it as new pillar clinical management. In this state-of-the-art review resulting from comprehensive literature search (Medline, Cochrane EMBASE), we describe impact SGLT2 on rehospitalizations HF propose therapeutic plan for maximizes benefits.